한국지질동맥경화학회 학술대회

This session, "Genetic Insights into Dyslipidemia and Diabetes: Pathways, Predictions, and Interventions," delves into the latest genetic advances impacting cardiovascular and metabolic diseases. Attendees will explore the evolving genetic landscape of cardiovascular disease (CVD) and diabetes, considering future implications for prediction and prevention. The second presentation examines the powers of multi-omics and multi-trait analyses in unraveling the complexity of metabolic disorders. Next, exciting developments in gene therapy for familial hypercholesterolemia will be showcased, highlighting cutting-edge interventions. The session concludes with an engaging discussion, fostering collaboration and reflection on how genetic research can translate into better clinical outcomes.

While TG have historically been overshadowed by the focus on LDL-C, the cumulative evidence suggests that they should not be ignored as a risk factor for CVD and should clearly be taken into account when assessing atherosclerotic residual risk. TG and their remnant cholesterol have direct implications in the pathogenesis of atherosclerotic CVD and their management could represent an additional therapeutic strategy. In this session, we will present the relationship of remnant cholesterol and ASCVD, furthermore sarcopenia. Although lack of clear evidence, recent strategy to target remnant cholesterol will be introduced. Through this session, we hope you to widen the scope of lipid management.

Symposium 13 will highlight current trends and regional advances in dyslipidemia management, shaping the future of lipid care in Asia. The session opens with an overview of the 2024 KSoLA Consensus on Secondary Dyslipidemia, presenting practical guidance on managing lipid disorders in patients with comorbid conditions. It will then shift to epidemiological and clinical insights from China and Japan, where speakers will discuss national trends, healthcare innovations, and evolving treatment strategies. This symposium provides an opportunity to understand how different healthcare systems approach dyslipidemia and to explore collaborative pathways for improving lipid management across diverse populations in the Asia-Pacific region.

Although luminal narrowing has traditionally guided our understanding of intracranial atherosclerosis and captured clinicians’ attention, growing evidence reveals that its impact reaches well beyond narrowing alone. This session, “What Is Important beyond Stenosis in Intracranial Atherosclerosis,” explores three key dimensions-vascular tortuosity and plaque burden, vessel wall enhancement and inflammation, and blood viscosity’s role in cerebral flow and stroke risk. Professor Mi-Yeon Eun, who is a stroke neurologist and neuro-interventionist from Kyungbook National University Chilgok Hospital, Republic of Korea, will present the relation between intracranial vascular tortuosity and overall atherosclerosis burden. Professor Dong-Wan Kang, a stroke neurologist from Seoul National University Bundang Hospital, Republic of Korea, will present the clinical impact of vascular enhancement and inflammation detected from high resolution vessel wall MRI. Professor Ho Geol Woo, a stroke neurologist and neuro-interventionist from Kyung Hee University Hospital, Republic of Korea, will present how blood viscosity affect development and stability of intracranial atherosclerosis. Together, these insights push us toward a more holistic approach to diagnosis and management of intracranial atherosclerosis.

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, yet many nontraditional risk factors are still underrecognized. This session highlights emerging contributors to ASCVD, offering new perspectives on disease development and progression. The first presentation explores how environmental pollution affects atherosclerosis through various biological mechanisms. The second addresses the impact of health inequity and social determinants on ASCVD risk. The final talk focuses on psychiatric disorders as an often-overlooked but important risk factor for ASCVD. By highlighting these topics, we aim to encourage a more comprehensive approach to ASCVD prevention.

Symposium 16 is titled “Defining the Optimal LDL-C Target for Prevention of Atherosclerotic Cardiovascular and Cerebrovascular Disease.” The session opens with a cardiologist’s perspective on establishing optimal LDL-C goals for secondary prevention in high-risk patients. The second presentation offers a neurologist’s insights into optimal LDL-C levels specifically for stroke prevention. Finally, an endocrinologist will review the evidence for varying LDL-C targets according to diabetes duration and discuss strategies for personalized guideline development. This symposium promises to deliver critical, evidence-based perspectives to bridge guideline recommendations with real-world clinical practice in cardiovascular and cerebrovascular disease prevention.

This session entitled “Emerging Drugs for Dyslipidemia Management” addresses innovative pharmacological strategies to tackle residual lipid risk that persists despite statin therapy. While LDL-C reduction remains the cornerstone of dyslipidemia management, a substantial number of patients continue to face elevated cardiovascular risk due to hypertriglyceridemia, elevated remnant cholesterol, or persistent atherogenic dyslipidemia. The first lecture will examine the real-world clinical applications of bempedoic acid and identify patient populations who may derive maximum therapeutic benefit. The second lecture will focus on APOC3 inhibition strategies for severe hypertriglyceridemia management, discussing clinical applicability in familial chylomicronemia syndrome and mixed dyslipidemia with supporting evidence from recent clinical trials. The final lecture will present the regulatory mechanisms of ANGPTL3 and ANGPTL8 in lipid metabolism and introduce the development status of next-generation therapeutic approaches targeting these pathways. Through this session, attendees will gain comprehensive insights into the latest paradigms in lipid-lowering therapy and future prospects for clinical implementation.

Sex and gender differences in cardiometabolic health have emerged as a critical dimension in precision medicine. This symposium will explore these complexities, ranging from biological and hormonal mechanisms to gender-informed differences in diagnosis and therapy. Professor Erin D. Michos from Johns Hopkins University, USA, will discuss mechanistic insights linking sex and cardiometabolic risk. Professor Ji Eun Lee from Korea University, Republic of Korea, will highlight how sex and gender influence cardiovascular risk assessment and biomarker interpretation. Finally, Professor Hyun Ju Yoon from Chonnam National University, Republic of Korea, will address the differential responses of men and women to cardiometabolic therapies. This session aims to highlight why sex-specific approaches are essential for accurate risk stratification and effective treatment in cardiometabolic disease.

Macrophage immunometabolism plays a pivotal role in orchestrating inflammation and repair in cardiovascular disease. This session will highlight emerging metabolic axes governing macrophage function in cardiometabolic injury and recovery. Professor Laurent Yvan-Charvet from INSERM, France, will introduce glutamine homeostasis as a previously overlooked regulator of cardiometabolic inflammation, shedding light on its immunomodulatory roles. Professor Edward Thorp from Northwestern University, USA, will present how myeloid cell metabolism influences both the amplification and resolution of cardiac inflammation, offering insights into innate immune reprogramming. Professor Yong Sook Kim from Chonnam National University, Republic of Korea, will present the therapeutic potential of ANGPTL4 in modulating inflammation and atherosclerosis. This session offers a comprehensive overview of the immunometabolic programming of macrophages and its translational relevance in cardiovascular injury and repair.